Viking Therapeutics, Inc.

VKTX

$2.98B

Mid Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO50 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jul 22, 2026

Market Overview

Stock performance and key metrics

VKTX News

Catalyst Timeline

2 upcoming, 1 past

No catalysts found.

2 more catalysts beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

Drug Pipeline

VK2735

Phase 3

Weight Loss

VK2809

Phase 2

NASH - Nonalcoholic Steatohepatitis

VK5211

Phase 2

Hip Fractures

Drug Name	Phase	Indication	Designations	Patent
VK2735	Phase 3	Weight Loss	-	-
VK2809	Phase 2	NASH - Nonalcoholic Steatohepatitis	-	-
VK5211	Phase 2	Hip Fractures	-	-

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Viking Therapeutics, Inc.

Market Overview

VKTX News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals